CLGN Stock Analysis: Buy, Sell, or Hold?
CLGN - CollPlant Biotechnologies Ltd Ordinary Shares
$0.40
0.00 (-0.05%)
▼
5d:
-2.49%
30d:
-4.33%
90d:
-36.52%
BUY
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 27, 2026
0d
Get Alerted When CLGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CLGN shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CLGN shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CLGN is currently trading at $0.40, which is considered slightly low relative to its 30-day fair value range of $0.39 to $0.43. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.2) compared to its historical average (3.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CLGN is in a strong downtrend. The price is currently testing key support at $0.39. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CLGN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.12 (+2680.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CLGN is in a strong downtrend. The price is currently testing key support at $0.39. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CLGN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.12 (+2680.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.39 -
$0.43
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 2680.7% below Wall St target ($11.12)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$0.39 -
$0.43
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.39
Resistance Level
$0.46
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.22
Wall Street Target
$11.12
(+2680.7%)
Revenue Growth (YoY)
-63.4%
PE vs Historical
-2.2 vs 3.5
CHEAP
Share & Embed Analysis
Last updated: June 03, 2026 11:12 PM ET
Data refreshes hourly during market hours. Next update: 12:12 AM
Data refreshes hourly during market hours. Next update: 12:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
